Sofi-cel is an investigational, off the shelf, fratricide-resistant allogeneic CD7 targeted CAR-T cell therapy under evaluation in a pivotal Phase 2 study for relapsed or refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL). This global study is enrolling pediatric and adult patients.

For more information, visit www.clinicaltrials.gov, study identifier number NCT06514794.